# Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)

> **NCT03645395** · PHASE2 · TERMINATED · sponsor: **Molecular Templates, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Non-hodgkin Lymphoma

## Interventions

- **DRUG:** MT-3724

## Key facts

- **NCT ID:** NCT03645395
- **Lead sponsor:** Molecular Templates, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-08
- **Primary completion:** 2021-03-10
- **Final completion:** 2021-03-10
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2022-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03645395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03645395, "Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03645395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*